GSK vs TAK: stock comparison and AI forecast
Gsk Plc (GSK) and Takeda Pharmaceutical Co Ltd (TAK) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GSK Gsk Plc
- Market Cap
- $103.19B
- P/E Ratio
- 5.6x
- Size
- large-cap
- AI Forecast
TAK Takeda Pharmaceutical Co Ltd
- Market Cap
- $62.51B
- P/E Ratio
- 6.0x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- GSK is 1.7 times larger than TAK by market capitalization ($103.19B against $62.51B).
- GSK trades at 5.6 times trailing earnings, TAK at 6.0 times.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GSK | TAK |
|---|---|---|
| Market Cap | $103.19B | $62.51B |
| P/E Ratio | 5.64x | 6.02x |
| EPS | $9.08 | $3.32 |
| Revenue/Share | $81.00 | $34.55 |
| FCF/Share | $15.23 | $6.79 |
Profitability & Margins
| Metric | GSK | TAK |
|---|---|---|
| Gross Margin | 70.8% | 67.4% |
| Operating Margin | 20.3% | 9.2% |
| Net Margin | – | 4.9% |
| EBT Margin | 18.2% | 5.5% |
| Tax Rate | 13.7% | 11.7% |
Financial Health
| Metric | GSK | TAK |
|---|---|---|
| Current Ratio | 0.82x | – |
| Quick Ratio | 0.54x | – |
| D/E Ratio | 2.76x | – |
| Working Capital | -$5.23B | – |
Cash Flow
| Metric | GSK | TAK |
|---|---|---|
| Operating Cash Flow | $37.61B | $25.43B |
| Free Cash Flow | $30.73B | $21.23B |
| Capital Spending | -$6.88B | -$4.20B |
| OCF Growth YoY | -13.3% | – |
| FCF Growth YoY | 0.0% | 0.0% |
| FCF/Sales | 18.8% | 19.7% |
| CapEx/Sales | 4.2% | 3.9% |
Operational Efficiency
| Metric | GSK | TAK |
|---|---|---|
| Receivables Turnover | 16.6x | – |
| Inventory Turnover | 6.1x | – |
| Fixed Assets Turnover | 13.3x | – |
| Days Sales Outstanding | 22 days | – |
| Days Inventory | 60 days | – |
| Payables Period | 155 days | – |
| Cash Conversion Cycle | -73 days | – |
Income Statement
| Metric | GSK | TAK |
|---|---|---|
| Total Revenue | $163.43B | $107.93B |
| Operating Income | $33.20B | $9.90B |
| Net Income | – | $5.25B |
| R&D Expense | $33.87B | $17.20B |
| SG&A Expense | $50.02B | – |
| Cost of Goods Sold | $47.81B | $35.17B |
Dividend & Shareholder Information
| Metric | GSK | TAK |
|---|---|---|
| Shares Outstanding | 2017M | 3124M |
| EPS Growth | 87.6% | – |
GSK vs TAK: stock comparison and AI forecast
Which is bigger, GSK or TAK?
GSK is 1.7 times larger than TAK by market capitalization ($103.19B against $62.51B).
Which is cheaper on earnings, GSK or TAK?
GSK trades at 5.6 times trailing earnings, TAK at 6.0 times.
Which one does Intratio's AI model rank higher, GSK or TAK?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.